Chemotherapy and Anti-angiogenic Agents- Induced Thrombosis in Cancer.
- To measure levels of circulating tissue factor (TF) in patients with newly diagnosed
multiple myeloma at several time points before, during, and after the administration of
chemotherapy and/or antiangiogenic agents.
- To measure the correlation of TF with two markers of coagulation activation (i.e.,
D-dimer, thrombin-antithrombin [TAT] complexes) and two markers of endothelial
activation (i.e., soluble E-selectin, soluble thrombomodulin) in these patients.
- To measure and compare (descriptively) our microparticle-associated TF procoagulant
activity assay with two other assays using samples from these patients.
OUTLINE: Patients undergo blood sample collection at baseline and then periodically during
treatment. Circulating tissue factor (TF) activity levels and coagulation and endothelial
activation (by ELISA) are measured. Medical charts are reviewed for sociodemographic and
After completion of study, patients are followed up for 3 months.
Time Perspective: Prospective
Levels of circulating tissue factor (TF)
Nigel Mackman, PhD
UNC Lineberger Comprehensive Cancer Center
United States: Institutional Review Board
|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill||Chapel Hill, North Carolina 27599-7570|